Precision Therapeutics for NF1-Associated Tumors: Improved Outcomes Through Targeted MEK Inhibition

Learn more about the expert recommended optimal management of patients with NF1-associated tumors from this on-demand webcast with downloadable slides and an expert-authored commentary with answers to frequently asked questions.

Share

Program Content

Activities

NF1 Current Understanding
NF1: Current State of Disease Understanding
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 21, 2024

Expires: November 20, 2025

NF1 Peripheral Nerve Sheath Tumors
NF1-Associated Peripheral Nerve Sheath Tumors
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 21, 2024

Expires: November 20, 2025

NF1 Gliomas
NF1-Associated Gliomas
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: November 22, 2024

Expires: November 21, 2025

Activities

Precision Therapeutics in NF1 Associated Tumors
Precision Therapeutics for NF1-Associated Tumors: Improved Outcomes Through Targeted MEK Inhibition
Video
Congratulations: You achieved a completion on 04/09/2022

Released: December 24, 2024

Expires: June 23, 2025

Activities

NF1-Associated Tumors FAQs
NF1-Associated Tumors and MEK Inhibitors: Answers to Your Questions
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 24, 2025

Expires: January 23, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.

Alexion Pharmaceuticals

SpringWorks Therapeutics, Inc.